Cardiology · Medical Literature
Quantitative PET coronary flow capacity and comprehensive management of chronic CAD: Lessons from the randomized CENTURY trial.
Abstract
Randomized trials in chronic coronary artery disease (CAD) tested single interventions of lifestyle, medical treatment, or revascularization. The randomized CENTURY trial tested a comprehensive strategy integrating intense lifestyle modification, medical treatment and revascularization reserved for severely reduced coronary flow capacity (CFC) by positron emission tomography (PET), for reducing death, myocardial infarction and revascularization compared with referring-cardiologist-directed standard community care. Participants with high risk factors, suspected or known CAD were randomly assigned to comprehensive or standard care. Rest-stress PET quantified CFC for physiological CAD severity at baseline, 2 and 5 years. Comprehensive care group reviewed PET results with frequent clinic visits and open 24/7 phone/email support. Standard care lacked supportive contact with blinded PET results, unblinded for severely reduced CFC with high mortality risk for potential revascularization. Of 1028 randomized participants, 515 were assigned to comprehensive care and 513 to standard care for the 5-year protocol with additional follow-up over next 5 to 11 years. Comprehensive vs standard care significantly decreased summed risk factor score at 5-years (P < 0.0001), all-cause death (4.7% vs. 8.2%; P = 0.023), death or MI (7.0% vs. 11.1%; P = 0.024), late revascularization (9.6% vs 14.8%; P = 0.011) and major adverse cardiac events (20.5% vs 29.9%; P = 0.0006). Only 56 of 1028 (5.4%) CENTURY patients had revascularization within 90 days guided by CFC severity, thereby reassuring and motivating patients and physicians for safely pursuing preventive risk factor goals while reserving angiogram-revascularization for high-risk, severe CFC. Intensity of adherence to comprehensive risk factor control during 5-years associated with additional significantly reduced death, MI and revascularizations over next 5 to 11 years. The randomised CENTURY trial demonstrates that comprehensive integrated lifestyle modification and optimal medical treatment with revascularization reserved for severely reduced CFC significantly reduced death, death or MI, and revascularization at 5 years and potentially over extended 5 to 11 years of non-predefined follow-up. (ClinicalTrials.gov NCT00756379).
Clinical relevance
Does a comprehensive strategy integrating intensive lifestyle modification, goal-directed medical therapy, and PET coronary flow capacity (CFC)-guided revascularization—reserved for severely reduced CFC—reduce all-cause death, myocardial infarction, and coronary revascularization compared with referring-cardiologist-directed standard community care in patients with chronic coronary artery disease or high cardiovascular risk? __SNAPSHOT__ {"studyDesign":"Randomized controlled trial (single-center) with 5-year protocol and additional non-predefined observational follow-up of 5–11 years; the Atherosclerosis 2026 paper (PMID 42435732) is a review/lessons-learned synthesis of the primary CENTURY trial results","setting":"Single academic center — Weatherhead PET Center for Preventing and Reversing Atherosclerosis, Division of Cardiology, McGovern Medical School / University of Texas and Memorial Hermann Hospital, Houston, TX, USA (NCT00756379)","sampleSize":"n = 1,028 (comprehensive care: n = 515; standard care: n = 513)","population":"Adults with high cardiovascular risk factors, suspected or known chronic stable coronary artery disease (CAD), including patients with diabetes, hypertension, dyslipidemia, metabolic syndrome, smoking, family history of premature CAD, or prior revascularization","intervention":"Comprehensive care: intensive lifestyle modification (diet, exercise, weight reduction, smoking cessation), aggressive medical management to predefined targets, frequent clinic visits (5 times in year 1, semiannually thereafter), 24/7 open phone/email support, serial PET imaging at baseline, 2, and 5 years with results reviewed with patients and physicians, and revascularization reserved for severely reduced CFC (CFR ≤1.27 and stress perfusion ≤0.83 mL/min/g as % of LV)","comparator":"Standard care: referring-cardiologist-directed community care; patients received AHA healthy-living guidelines at baseline visit and were returned to their referring physician without follow-up appointments or support contact by the CENTURY team; PET results were blinded except in patients with severely reduced CFC and high mortality risk, in whom results were unblinded for potential revascularization","primaryOutcome":"CENTURY summed risk factor score reduction at 5 years (composite cardiovascular risk score); secondary endpoint: composite of all-cause death, non-fatal myocardial infarction, stroke, and coronary revascularization","followUp":"Pre-specified protocol: 5 years; additional non-predefined observational follow-up: 5–11 years (total up to 11 years for some participants)","fundingSource":"Non-profit/philanthropic — internal funds of the Weatherhead PET Center, Weatherhead Foundation, and Weatherhead Endowment at UT Health Science Center Houston; no industry support or author conflicts of interest declared"}
Key findings
At 5 years, comprehensive care significantly reduced the primary endpoint (CENTURY summed risk factor score; p < 0.0001; score change Δ−1.1 vs. +0.33 for standard care; 95% CI −1.84 to −0.97). For secondary clinical endpoints, comprehensive versus standard care reduced: all-cause death (4.7% vs. 8.2%; absolute risk difference [ARD] −3.5 percentage points [calculated]; p = 0.023), death or MI (7.0% vs. 11.1%; ARD −4.1 percentage points [calculated]; p = 0.024), late revascularization (9.6% vs. 14.8%; ARD −5.2 percentage points [calculated]; p = 0.011), and major adverse cardiac events (MACE) (20.5% vs. 29.9%; ARD −9.4 percentage points [calculated]; p = 0.0006). Relative risk reductions: ~43% for all-cause death, ~37% for death/MI, ~35% for late revascularization, and ~31% for MACE (all calculated). NNT for MACE prevention over 5 years ≈ 11 (calculated). Intensity of adherence to comprehensive risk factor control during 5 years was associated with additional significant reductions in death, MI, and revascularization during the subsequent non-predefined 5–11 year follow-up period. Only 56 of 1,028 participants (5.4%) underwent revascularization within 90 days, guided by severely reduced CFC severity; when CFC was not severely reduced, the revascularization rate was 0.4%. No specific adverse event rates were reported in the available abstract. Hazard ratios and confidence intervals for clinical endpoints other than the risk score were not reported in the abstract.
Practice implications
The CENTURY trial establishes that, in patients with chronic CAD or high cardiovascular risk at a single specialized academic PET center, a comprehensive strategy integrating intensive lifestyle modification, goal-directed medical therapy, and quantitative PET-CFC-guided selective revascularization significantly reduced all-cause death, the composite of death or MI, late revascularization, and MACE over 5 years compared with referring-cardiologist-directed standard community care. The trial demonstrates that PET-CFC can function as a high-precision gatekeeper for revascularization decisions, enabling safe deferral of invasive procedures in the vast majority of patients (94.6% did not undergo early revascularization) while reserving intervention for those with objectively severe, high-mortality-risk coronary physiology. What the trial does NOT establish: (1) The relative contributions of lifestyle modification, pharmacotherapy intensification, and PET-guided revascularization to outcome benefit cannot be individually isolated, as the intervention was a bundled strategy. (2) The 5–11 year extended follow-up was non-predefined and observational, and its results must be interpreted as hypothesis-generating only. (3) The Atherosclerosis 2026 paper (PMID 42435732) represents a review and lessons-learned synthesis based on the primary EHJ publication; only the abstract was available for this summary — the full-text conclusions, subgroup analyses, and methodological details may contain important additional nuance. (4) Applicability may be limited for patients unable to access cardiac PET imaging, those unwilling or unable to engage in intensive lifestyle modification programs, or those managed outside high-resource academic centers with dedicated nurse-navigator and 24/7 support infrastructure. Women, elderly patients, and racial/ethnic minorities may not be adequately represented given the single-center design; demographic details were not reported in the available abstract. Clinicians should note that the intensive support structure (frequent clinic visits, 24/7 availability) embedded in the comprehensive arm represents a resource investment that is not uniformly available in community practice, raising important questions of scalability and generalizability. __LIMITATIONS__ Single-center design at a highly specialized PET imaging center with dedicated lifestyle-modification infrastructure, substantially limiting external generalizability to community cardiology practice.,The intervention is a multi-component bundle (lifestyle + pharmacotherapy + PET-guided revascularization); the independent contribution of each component to the observed outcomes cannot be determined from this study design.,The primary endpoint (CENTURY risk score) is a composite risk score rather than a hard clinical endpoint; clinical importance relative to the secondary MACE endpoints requires careful interpretation.,The extended follow-up period (5–11 years) was non-predefined and observational, creating risk of selection bias, informative censoring, and confounding over time; these data should not be treated as equivalent to a randomized endpoint.,No hazard ratios or confidence intervals for the clinical endpoints (death, death/MI, revascularization, MACE) were available in the abstract, precluding full assessment of effect precision.,Potential differential ascertainment of events between groups given that the comprehensive care group had more frequent clinical contact (surveillance bias).,Blinding was partial by design: standard care patients with severely reduced CFC had their PET results unblinded, potentially enriching the standard care arm with patients at very high risk who then received revascularization, which could paradoxically reduce the apparent standard-care outcome disadvantage.,Baseline patient demographic characteristics, extent of known vs. suspected CAD, and medication use were not reported in the available abstract, limiting assessment of baseline comparability.,No safety or adverse event data (e.g., radiation exposure from serial PET, revascularization complications) were reported in the abstract.,No direct comparison to high-intensity statin therapy alone or to ISCHEMIA-trial-style optimal medical therapy, making it difficult to isolate the incremental benefit of PET-guided decision-making beyond aggressive pharmacotherapy.,This review/lessons-learned article (2026) summarizes findings from the primary trial publication (EHJ 2025); only the abstract was available for this summary, which is a critical limitation. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ The randomized CENTURY trial demonstrates that a comprehensive, bundled strategy—intensive lifestyle modification, goal-directed medical therapy, and PET coronary flow capacity-guided selective revascularization—significantly reduced all-cause death, death/MI, late revascularization, and MACE over 5 years versus standard community care in chronic CAD, with an NNT for MACE prevention of approximately 11 (calculated). The strategy safely deferred revascularization in over 94% of participants without early invasive procedures. Broad adoption requires access to quantitative cardiac PET, intensive multidisciplinary support infrastructure, and confirmation that these benefits are replicable outside a single specialized academic center.